A plasma matrix-based biomaterial, its preparation method and application

By loading active factors from plasma matrix exudate onto a plasma matrix membrane and lyophilizing it, the problems of rapid degradation and insufficient bioactivity of traditional plasma matrix membranes are solved, resulting in a plasma matrix-based biomaterial with high bioactivity and antibacterial properties, suitable for multiple tissue regeneration fields.

CN117462764BActive Publication Date: 2026-11-17HUBEI PRIME SHIELD BIOTECHNOLOGY CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202311575718.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-21
Publication Date
2026-11-17
Estimated Expiration
2043-11-21

AI Technical Summary

Technical Problem

Traditional plasma matrix membranes degrade rapidly, have insufficient biological activity, and require immediate preparation and use, which limits their application scope and operability in clinical practice.

Method used

Plasma matrix-based biomaterials are prepared by immersing plasma matrix membranes in plasma matrix exudate and loading them with active factors. These biomaterials can be freeze-dried to enhance their bioactivity and antibacterial properties, providing flexibility and operability.

Benefits of technology

It improves the bioactivity and antibacterial properties of the plasma matrix membrane, enhances tissue regeneration, and is applicable to wound healing, soft tissue repair, and bone regeneration, providing greater flexibility and operability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117462764B_ABST
    Figure CN117462764B_ABST
Patent Text Reader

Abstract

This invention relates to a plasma matrix-based biomaterial, its preparation method, and its applications. The preparation method involves immersing a plasma matrix membrane in a plasma matrix exudate solution. The preparation method provided by this invention overcomes the limitations of traditional plasma matrix preparation methods, improves the bioactivity and antibacterial properties of the material, and offers greater flexibility and operability. The plasma matrix-based biomaterial prepared by this invention possesses biocompatibility, high bioactivity, and antibacterial properties, can promote tissue regeneration, enhance therapeutic effects, and can be applied in multiple fields such as wound healing, soft tissue repair, and bone regeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomaterials technology, and in particular to a plasma matrix-based biomaterial, its preparation method, and its application. Background Technology

[0002] Biomaterials play a crucial role in the field of tissue regeneration. Plasma matrix is ​​a commonly used biomaterial, which is derived from the patient's own blood. It has good biocompatibility and bioactivity and can be used for wound healing, bone regeneration barrier membranes, bone regeneration materials and soft tissue repair, with good results and wide application.

[0003] Plasma matrix membranes, made from plasma matrix, can be applied in oral clinical practice. Tooth loss, inflammation, disease, tumors, and other conditions often lead to alveolar bone and soft tissue defects, frequently requiring guided bone regeneration (BRB) for treatment. In BRB, the plasma matrix membrane can be shredded and mixed with bone regeneration materials, or used as a barrier membrane to isolate external soft tissue from ingrowth into the bone defect and promote healing of oral mucosa and soft tissue. However, traditional plasma matrix membranes still suffer from rapid degradation and insufficient bioregenerative activity. Furthermore, existing plasma matrix membranes require immediate preparation and use, lacking flexibility, which limits their clinical application and operability.

[0004] Therefore, it is necessary to develop a novel plasma matrix-based biomaterial and its preparation method to improve its bioactivity and provide greater flexibility. Summary of the Invention

[0005] To address the aforementioned technical problems, this invention provides a plasma matrix-based biomaterial, its preparation method, and its applications. The plasma matrix-based biomaterial provided by this invention possesses biocompatibility, high bioactivity, and antibacterial properties, promoting tissue regeneration and enhancing therapeutic effects. It can be applied in multiple fields such as wound healing, soft tissue repair, and bone regeneration. Furthermore, the preparation method provided by this invention allows for the pre-preparation and cryopreservation of the biomaterial, reducing intraoperative operation time and providing greater flexibility and operability for use when needed.

[0006] In a first aspect, the present invention provides a method for preparing a plasma matrix-based biomaterial, the method comprising immersing a plasma matrix membrane in a plasma matrix exudate solution.

[0007] The preparation method provided by this invention uses plasma matrix exudate to treat the plasma matrix membrane, which can load the active factors in the plasma matrix exudate onto the plasma matrix membrane, thereby improving the bioactivity of the plasma matrix membrane and avoiding the waste of effective components in the traditional plasma matrix preparation process.

[0008] As a preferred embodiment of the present invention, the preparation method further includes centrifuging blood to obtain a plasma matrix clot, pressing it into a membrane to obtain a plasma matrix membrane and a plasma matrix exudate.

[0009] During the preparation of the plasma matrix membrane, a large amount of exudate, namely plasma matrix exudate, is generated. This exudate contains many active factors, such as growth factors, extracellular vesicles, and complement proteins. This invention improves the bioactivity and antibacterial properties of the plasma matrix membrane by attaching the plasma matrix exudate to the plasma matrix membrane.

[0010] As a preferred embodiment of the present invention, the centrifugal force of the centrifugation is 300-1000g, such as 400g, 500g, 600g, 700g, 800g, 900g, etc., where g is the unit of centrifugal force, representing how many Gs, i.e., gravitational acceleration.

[0011] As a preferred embodiment of the present invention, the centrifugation time is 2 to 10 minutes, such as 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, etc.

[0012] This invention involves collecting whole blood and centrifuging it to separate the upper yellow gel-like solid, which is the plasma matrix clot. During the collection of the plasma matrix clot, it is also necessary to carefully separate and remove the red blood cell layer adhering to the plasma matrix clot.

[0013] As a preferred embodiment of the present invention, the pressure during the pressing process is 1 to 5 N, for example, 2 N, 3 N, 4 N, etc.

[0014] The present invention performs a compression molding operation on the obtained plasma matrix clot to compress the plasma matrix clot into a membrane structure. During this process, an appropriate pressure must be selected, otherwise it is easy to break during the subsequent freeze-drying process.

[0015] As a preferred embodiment of the present invention, the preparation method further includes freeze-drying the plasma matrix membrane before placing it in the plasma matrix exudate.

[0016] The plasma matrix membrane obtained in this invention can be used immediately. If not used immediately, it can be lyophilized to maintain the stability of its structure and active ingredients and enhance its preservation performance. This invention does not impose excessive limitations on the apparatus used for lyophilization; any apparatus that can achieve the purpose of this invention is applicable. For example, a freezer or other refrigeration equipment can be used for the lyophilization process.

[0017] As a preferred embodiment of the present invention, the freeze-dried product is stored at -80℃ to -20℃, for example, -70℃, -60℃, -50℃, -40℃, -30℃, etc.

[0018] When the plasma matrix membrane prepared by this invention is not used immediately, it can be freeze-dried and stored in an environment of -80℃ to -20℃ to maintain the stability of its structure and active ingredients. When needed, it can be taken out and immersed in plasma matrix exudate. This method can reduce intraoperative operation time and has greater flexibility and operability.

[0019] As a preferred embodiment of the present invention, the preparation method further includes centrifuging the plasma matrix exudate before placing the plasma matrix membrane in the plasma matrix exudate to obtain the effective components, and then resuspending them.

[0020] In the preparation method of this invention, a large amount of plasma matrix exudate flows out during the membrane pressing operation. On the one hand, because the plasma matrix exudate has a large volume, directly placing the plasma matrix membrane in the plasma matrix exudate results in low loading efficiency; on the other hand, if the plasma matrix membrane is not used immediately, directly placing it in the plasma matrix exudate also leads to material waste. Therefore, this invention centrifuges the plasma matrix exudate to obtain its effective components. When needed, the membrane is resuspended, and then immersed in the resuspension solution, which improves efficiency and provides greater flexibility and operability.

[0021] As a preferred embodiment of the present invention, the centrifugation separation includes sequentially performing low-speed centrifugation and high-speed centrifugation on the plasma matrix exudate.

[0022] The present invention first removes cellular components from the plasma matrix exudate by low-speed centrifugation to obtain a supernatant, which is then collected. The supernatant is then centrifuged at high speed to obtain a precipitate, which is the effective component.

[0023] As a preferred embodiment of the present invention, the centrifugal force of the low-speed centrifugation is 1000-2000g, such as 1200g, 1400g, 1600g, 1800g, etc.

[0024] As a preferred embodiment of the present invention, the low-speed centrifugation time is 5 to 30 minutes, for example, 10 minutes, 15 minutes, 20 minutes, 25 minutes, etc.

[0025] As a preferred embodiment of the present invention, the centrifugal force of the high-speed centrifuge is 50,000 to 150,000 g, such as 60,000 g, 80,000 g, 100,000 g, 120,000 g, 140,000 g, etc.

[0026] As a preferred embodiment of the present invention, the high-speed centrifugation time is 30 to 100 minutes, such as 40 minutes, 50 minutes, 60 minutes, 70 minutes, 80 minutes, 90 minutes, etc.

[0027] As a preferred embodiment of the present invention, the active ingredients include exosomes, microvesicles, and complement proteins.

[0028] As a preferred technical solution of the present invention, the effective components are further stored at -80℃ to -20℃ before resuspension. As mentioned above, when the plasma matrix membrane prepared by the present invention is not used immediately, the effective components can be stored and resuspended when needed. Then the plasma matrix membrane is immersed in the resuspension solution, which has greater flexibility and operability.

[0029] As a preferred embodiment of the present invention, the volume content of the effective component in the resuspension is 1-20%, for example, 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, etc.

[0030] This invention does not impose excessive limitations on the solvents used for resuspension; any solvent that can achieve the purpose of this invention is applicable to this invention.

[0031] As a preferred embodiment of the present invention, the solvent used for resuspension includes physiological saline, cell culture medium or other suitable physiological fluids.

[0032] As a preferred embodiment of the present invention, the volume of the solvent used for resuspension is 0.1 to 10 mL, for example, 0.5 mL, 1 mL, 2 mL, 4 mL, 6 mL, 8 mL, etc.

[0033] The present invention uses too much solvent during resuspension, resulting in low loading efficiency; or uses too little solvent, insufficient to completely soak the plasma matrix membrane. Therefore, the present invention provides a suitable resuspension solvent volume between 0.1 and 10 mL.

[0034] As a preferred embodiment of the present invention, the soaking time is 1 to 10 minutes, for example, 2 minutes, 4 minutes, 6 minutes, 8 minutes, etc.

[0035] The present invention does not impose too many limitations on the soaking operation. It can be to directly immerse the plasma matrix membrane completely in the resuspension, or to drop the resuspension onto the surface of the plasma matrix membrane until it is completely soaked, as long as the plasma matrix membrane is completely wetted.

[0036] This invention completely immerses the plasma matrix membrane in a resuspension to fully wet it, thereby restoring its operability and improving its softness and plasticity, allowing active ingredients to adhere to it and making it more suitable for clinical applications in tissue regeneration.

[0037] As a specific embodiment of the present invention, the preparation method includes the following steps:

[0038] (1) The blood is centrifuged to obtain a plasma matrix clot, and a membrane is formed by pressing with a pressure of 1-5N to obtain a plasma matrix membrane and plasma matrix exudate. The centrifugation force is 300-1000g and the time is 2-10min.

[0039] (2) The plasma matrix membrane was freeze-dried and then stored at -80℃ to -20℃;

[0040] (3) The plasma matrix exudate was subjected to low-speed centrifugation and high-speed centrifugation in sequence to obtain the effective components, and then resuspended. The centrifugal force of the low-speed centrifugation was 1000-2000g and the time was 5-30min. The centrifugal force of the high-speed centrifugation was 50000-150000g and the time was 30-100min.

[0041] (4) The freeze-dried plasma matrix membrane is immersed in the resuspension obtained in step (3).

[0042] It should be noted that in the preparation method provided by the present invention, the obtained effective components and lyophilized plasma matrix membrane can be processed according to actual needs. That is, when immediate use is required, the effective components are resuspended and the lyophilized plasma matrix membrane is immersed in the resuspension solution to obtain the plasma matrix-based biomaterial of the present invention. If immediate use is not required, the effective components and lyophilized plasma matrix membrane can be stored at -80℃ to -20℃ respectively. When needed, they can be taken out and the preparation can be completed. This method has greater flexibility, allows for advance blood collection, preparation and storage, and convenient direct use during surgery.

[0043] The preparation method provided by this invention loads the effective components of plasma matrix exudate onto a plasma matrix membrane, resulting in a plasma matrix-based biomaterial with high bioactivity, antibacterial properties, easy storage, and good operability. This preparation method overcomes the limitations of traditional plasma matrix preparation methods, improves the bioactivity and antibacterial properties of the material, and provides greater flexibility and operability. This innovation is expected to play an important role in the field of tissue regeneration and provide better solutions for clinical applications.

[0044] Secondly, the present invention provides plasma matrix-based biomaterials prepared by the preparation method described in the first aspect.

[0045] The plasma matrix-based biomaterial provided by this invention retains effective components such as exosomes, microvesicles, and complement proteins in the plasma matrix exudate. On the one hand, it avoids the waste of effective components, and on the other hand, it improves the bioactivity and antibacterial properties of the plasma matrix-based biomaterial. It can provide more active factors and nutrients for tissue regeneration, enhance the therapeutic effect, and can be used for tissue regeneration or as a barrier membrane for biomaterials or as a material combined with bone regeneration materials.

[0046] Thirdly, the present invention provides the application of the plasma matrix-based biomaterials described in the second aspect in guiding bone regeneration barrier membranes, bone regeneration materials, and wound covering membranes.

[0047] The plasma matrix-based biomaterials provided by this invention have good biocompatibility and bioactivity, and can be applied to various tissue regeneration fields, such as bone regeneration, soft tissue repair, wound healing, etc. Specifically, they can be applied to guide bone regeneration barrier membranes, bone regeneration materials, and wound covering membranes. Due to the flexibility of the preparation method and the advantages of resource utilization of this invention, it is suitable for different clinical needs and treatment plans.

[0048] The technical solution provided by the embodiments of the present invention has the following advantages compared with the prior art:

[0049] 1. The preparation method provided by the present invention overcomes the limitations of traditional plasma matrix preparation methods, improves the bioactivity and antibacterial properties of the material, and provides greater flexibility and operability.

[0050] 2. The plasma matrix-based biomaterials prepared by this invention have biocompatibility, high bioactivity and antibacterial properties, can promote tissue regeneration and enhance the therapeutic effect, and can be applied to multiple fields such as wound healing, soft tissue repair and bone regeneration. Attached Figure Description

[0051] The accompanying drawings, which are incorporated in and form part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.

[0052] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, for those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0053] Figure 1 The effect of different addition ratios of the effective components of the plasma matrix exudate obtained in Example 1 of the present invention on the growth of Escherichia coli;

[0054] The figures from left to right represent the addition percentages of the active ingredient at different cultivation stages: 0%, 1%, 5%, 10%, and 20%.

[0055] Figure 2 The effect of different addition ratios of the effective components of the plasma matrix exudate obtained in Example 1 of the present invention on the growth of Staphylococcus aureus;

[0056] The figures from left to right represent the addition percentages of the active ingredient at different cultivation stages: 0%, 1%, 5%, 10%, and 20%.

[0057] Figure 3 The effect of the plasma matrix-based biomaterial obtained in Example 2 of this invention as a wound covering membrane on the migration of gingival fibroblasts. Detailed Implementation

[0058] To better understand the above-mentioned objectives, features, and advantages of the present invention, the solutions of the present invention will be further described below. It should be noted that, unless otherwise specified, the embodiments of the present invention and the features thereof can be combined with each other.

[0059] Many specific details are set forth in the following description in order to provide a full understanding of the invention, but the invention may also be practiced in other ways different from those described herein; obviously, the embodiments in the specification are only some embodiments of the invention, and not all embodiments.

[0060] Example 1

[0061] This embodiment provides a plasma matrix-based biomaterial and its preparation method, the preparation method comprising the following steps:

[0062] (1) Draw 20 mL of fresh blood from a healthy volunteer into two blood collection tubes for plasma matrix, centrifuge them at a centrifugation force of 700 g for 8 min to obtain plasma matrix clots, pick them up with special tweezers, then stack the two plasma matrix clots together and place them in a special plasma matrix instrument box. Press the membrane with a pressure of 1 N to obtain a plasma matrix membrane, and collect the plasma matrix exudate with a syringe.

[0063] (2) The plasma matrix membrane was freeze-dried to enhance its stability and preservation performance, and stored at -80℃;

[0064] (3) Centrifuge the plasma matrix exudate. First, centrifuge at 1000g for 5 minutes and collect the supernatant. Then, centrifuge the supernatant at 120000g for 90 minutes and discard the supernatant to obtain the precipitate, which is the active ingredient, containing exosomes, microvesicles and complement proteins, etc. Store at -80℃. Then, dissolve the active ingredient in 1mL of physiological saline and resuspend it to make it biologically active.

[0065] (4) Drop the resuspended liquid obtained in step (3) onto the surface of the lyophilized plasma matrix membrane to completely immerse and wet it for 5 minutes to obtain the plasma matrix-based biomaterial.

[0066] Example 2

[0067] This embodiment provides a plasma matrix-based biomaterial and its preparation method, the preparation method comprising the following steps:

[0068] (1) Draw 20 mL of fresh blood from a healthy volunteer into two blood collection tubes for plasma matrix, centrifuge them at a centrifugation force of 300 g for 10 min to obtain plasma matrix clots, pick them up with special tweezers, then stack the two plasma matrix clots together and place them in a special plasma matrix instrument box. Press the membrane with a pressure of 5 N to obtain a plasma matrix membrane, and collect the plasma matrix exudate with a syringe.

[0069] (2) The plasma matrix membrane was freeze-dried to enhance its stability and preservation performance, and stored at -50℃;

[0070] (3) Centrifuge the plasma matrix exudate. First, centrifuge at 2000g for 15min and collect the supernatant. Then, centrifuge the supernatant at 150000g for 30min and discard the supernatant to obtain the precipitate, which is the active ingredient, containing exosomes, microvesicles and complement proteins, etc., and store it at -50℃. Then, dissolve the active ingredient in 0.1mL of physiological saline and resuspend it to make it biologically active.

[0071] (4) Drop the resuspended liquid obtained in step (3) onto the surface of the lyophilized plasma matrix membrane to completely immerse and wet it for 1 minute to obtain the plasma matrix-based biomaterial.

[0072] Example 3

[0073] This embodiment provides a plasma matrix-based biomaterial and its preparation method, the preparation method comprising the following steps:

[0074] (1) Draw 20 mL of fresh blood from a healthy volunteer into two blood collection tubes for plasma matrix, centrifuge them at a centrifugation force of 1000 g for 2 min to obtain plasma matrix clots, pick them up with special tweezers, then stack the two plasma matrix clots together and place them in a special plasma matrix instrument box. Press the membrane with a pressure of 3 N to obtain a plasma matrix membrane, and collect the plasma matrix exudate with a syringe.

[0075] (2) The plasma matrix membrane was freeze-dried to enhance its stability and preservation performance, and stored at -20℃;

[0076] (3) Centrifuge the plasma matrix exudate. First, centrifuge at 1500g for 30min and collect the supernatant. Then, centrifuge the supernatant at 50000g for 60min and discard the supernatant to obtain the precipitate, which is the active ingredient, containing exosomes, microvesicles and complement proteins, etc., and store it at -20℃. Then, dissolve the active ingredient in 10mL of physiological saline and resuspend it to make it biologically active.

[0077] (4) Drop the resuspended liquid obtained in step (3) onto the surface of the lyophilized plasma matrix membrane to completely immerse and wet it for 10 minutes to obtain the plasma matrix-based biomaterial.

[0078] Example 4

[0079] This embodiment provides a plasma matrix-based biomaterial and its preparation method, the preparation method comprising the following steps:

[0080] (1) Draw 20 mL of fresh blood from a healthy volunteer into two blood collection tubes for plasma matrix, centrifuge them at a centrifugation force of 700 g for 8 min to obtain plasma matrix clots, pick them up with special tweezers, then stack the two plasma matrix clots together and place them in a special plasma matrix instrument box. Press the membrane with a pressure of 1 N to obtain a plasma matrix membrane, and collect the plasma matrix exudate with a syringe.

[0081] (2) Centrifuge the plasma matrix exudate. First, centrifuge at 1000g for 5 minutes and collect the supernatant. Then, centrifuge the supernatant at 120000g for 90 minutes and discard the supernatant to obtain the precipitate, which is the active ingredient, which contains exosomes, microvesicles and complement proteins. Then, dissolve the active ingredient in 1mL of physiological saline and resuspend it to make it biologically active.

[0082] (3) Drop the resuspended liquid obtained in step (2) onto the surface of the plasma matrix membrane to completely immerse and wet it for 5 minutes to obtain the plasma matrix-based biomaterial.

[0083] Performance Test 1

[0084] The effective components of the plasma matrix exudate obtained in step (3) of Example 1 were added to LB medium of Escherichia coli with a concentration of 10^6 CFU / ml at volume concentrations of 0%, 1%, 5%, 10%, and 20% for 36 h. The absorbance values ​​at 600 nm after 4.5 h, 15 h, and 36 h of culture were measured by spectrophotometry. The results are as follows: Figure 1 As shown.

[0085] The effective components of the plasma matrix exudate obtained in step (3) of Example 1 were added to LB medium containing Staphylococcus aureus at a volume concentration of 0%, 1%, 5%, 10%, and 20% at a concentration of 10^6 CFU / ml and cultured for 36 h. The absorbance at 600 nm was measured by spectrophotometry after 4.5 h, 15 h, and 36 h of culture, respectively. The results are as follows: Figure 2 As shown.

[0086] Figure 1 This study investigates the effect of different addition ratios of the effective components of the plasma matrix exudate obtained in Example 1 of the present invention on the growth of Escherichia coli. Figure 2 This study investigates the effect of different addition ratios of the effective components of the plasma matrix exudate obtained in Example 1 of this invention on the growth of Staphylococcus aureus. Figure 1 and Figure 2 It is known that adding different proportions of the effective components of the plasma matrix exudate provided by the present invention can inhibit bacterial growth to varying degrees, indicating that the effective components of the plasma matrix exudate have strong antibacterial properties, and loading them onto the plasma matrix membrane can effectively improve the antibacterial properties of the plasma matrix membrane.

[0087] Application Example 1

[0088] In this application example, the plasma matrix-based biomaterial obtained in Example 1 was used in oral bone defect areas as a barrier to guide bone regeneration. It was found that it could promote the proliferation and differentiation of osteocytes, thereby promoting the regeneration and repair of bone tissue, and could better resist infection.

[0089] Application Example 2

[0090] In this application example, plasma-based biomaterials were prepared according to the preparation method of Example 1, and the volume content of the effective components in 1 mL of physiological saline during resuspension in step 3 was 1% and 5%, respectively. The prepared plasma-based biomaterials were used on the surface of oral mucosal wounds as a wound covering membrane. Cell migration experiments were performed on gingival fibroblasts, and the results are as follows... Figure 3 As shown.

[0091] Figure 3This study investigates the effects of plasma matrix-based biomaterials (1% and 5% effective ingredient content) and plasma matrix (0 effective ingredient content) obtained in this invention as wound covering films on gingival fibroblast migration. It was found that when using the plasma matrix-based biomaterial of this invention as a wound covering film, the shorter the distance between the two dashed lines after 24 hours, the faster the cell migration. This indicates that the plasma matrix-based biomaterial prepared in this invention can promote cell migration and regeneration, playing a protective and healing-promoting role, and accelerating the wound healing process.

[0092] It should be noted that, in this document, relational terms such as "first" and "second" are used merely to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.

[0093] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the present invention is not to be limited to the embodiments described herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A method for preparing a plasma matrix-based biomaterial, characterized in that, The preparation method includes: (1) Centrifuge the blood to obtain a plasma matrix clot, press the plasma matrix clot into a membrane to obtain a plasma matrix membrane and a plasma matrix exudate, wherein the plasma matrix exudate is the liquid generated during the pressing of the plasma matrix clot into a membrane; (2) The plasma matrix exudate is centrifuged for the first time at a centrifugal force of 1000-2000g, and the supernatant is collected; the supernatant is centrifuged for the second time at a centrifugal force of 50000-150000g to obtain the active ingredient, and the active ingredient is resuspended, wherein the active ingredient includes exosomes, microvesicles and complement proteins, and the volume content of the active ingredient in the resuspended solution is 1-20%; (3) The plasma matrix membrane is immersed in the resuspension solution to obtain plasma matrix-based biomaterial.

2. The preparation method according to claim 1, characterized in that, In step (1), the centrifugal force when centrifuging blood to obtain plasma matrix clots is 300~1000 g, and the centrifugation time is 2~10 min; the pressure when pressing the plasma matrix clots is 1~5 N.

3. The preparation method according to claim 1, characterized in that, The plasma matrix membrane is lyophilized before being placed in the resuspension.

4. The preparation method according to claim 3, characterized in that, The lyophilized plasma matrix membrane was stored at -80℃ to -20℃.

5. The preparation method according to claim 1, characterized in that, The first centrifugation time is 5-30 min, and the second centrifugation time is 30-100 min.

6. The preparation method according to claim 1, characterized in that, Prior to resuspension, the active ingredient is stored at -80℃ to -20℃.

7. The preparation method according to claim 1, characterized in that, The solvents used for resuspension include physiological saline and cell culture medium.

8. The preparation method according to claim 1, characterized in that, The volume of the solvent used for resuspension is 0.1~10 mL.

9. The preparation method according to claim 1, characterized in that, The soaking time is 1 to 10 minutes.

10. A plasma matrix-based biomaterial, characterized in that, It includes a plasma matrix membrane and effective components derived from plasma matrix exudate loaded on the plasma matrix membrane, the effective components including exosomes, microvesicles and complement proteins; The plasma matrix-based biomaterial is prepared by the preparation method according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Stem cell exosome patch and preparation method and application thereof

    CN104894062A

  • Separation and extraction method for cytomembrane microvesicles (MVs) and exosomes (EXs)

    CN105716928A

  • Silver nanoparticle improved plasma matrix and plasma matrix membrane preparation method and application

    CN115887787A

  • Preparation method of gold nanoparticle improved plasma matrix and plasma matrix membrane

    CN115887788A

  • Biological material impregnated with lipid vesicles

    FR3124696A1